Straits Times Index
3,346.14 +7.20 (+0.22%) Nikkei
38,449.51 -387.95 (-1.00%) Hang Seng
18,501.99 +57.88 (+0.31%) FTSE 100
8,232.04 -30.71 (-0.37%) Bitcoin USD
71,023.59 +1,952.18 (+2.83%) CMC Crypto 200
1,477.24 +30.09 (+2.08%)
Protalix BioTherapeutics, Inc. (PLX)
After hours:
| Previous close | 1.1500 |
| Open | 1.1500 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 800 |
| Day's range | 1.1100 - 1.1600 |
| 52-week range | 1.0300 - 2.5100 |
| Volume | |
| Avg. volume | 430,633 |
| Market cap | 82.847M |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | 14.12 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that Dror Bashan, its President and Chief Executive Officer, will present at the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California. Mr. Bashan will provide senior biotech executives, busi
- PR Newswire
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.
- PR Newswire
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.
